Nasdaq
$9.74▲ 0.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.60BShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 10.16After-hours26.10.17 05:30SCHEDULE 13GOwnership#●●●#●●●
NOVAVAX INC
Shah Capital Management has filed a Schedule 13G, reporting a beneficial ownership of more than 5% of Novavax Inc. This filing officially confirms the firm's significant equity position in the company.…more
$9.74+0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:15SCHEDULE 13D/AOwnership
NOVAVAX INC
Shah Capital Management has filed a SCHEDULE 13D/A regarding its beneficial ownership in Novavax, Inc. This filing serves to report updates to the existing equity holdings of Shah Capital Management in the company.…more
$9.74+0.46%vs prev closeView filingShare - 8.7Regular26.08.07 23:26SCHEDULE 13GOwnership
NOVAVAX INC
스테이트 스트리트(State Street Corp)가 노바백스(Novavax Inc)의 지분 보유 현황을 보고하는 Schedule 13G 공시를 제출했습니다. 이는 기관 투자자가 특정 기업의 지분을 5% 이상 보유하게 되었을 때 의무적으로 보고하는 대량보유상황보고서입니다.…more
$9.74+0.46%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 05:24#●●●
Shah Capital Withdraws SEC Registration, Shifts Novavax Stake to Passive Holding…more
Shah Capital has voluntarily withdrawn its SEC registration as an investment adviser and will no longer hold Novavax shares for the purpose of influencing control. The firm intends to report its future holdings of the company via Schedule 13G filings.…more
$9.74+0.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.8Pre-market26.10.08 18:59
●●●●●●●● ●●●●● ●●●●●●
Russian authorities have officially denied media reports regarding a second case of illness in the Siberia region. This development does not contain specific economic data or corporate information that would impact the markets.…more
$9.74+0.46%vs prev closeShareBenzinga - 8.28Pre-market26.08.28 21:34
●●●●●●●● ●●●●● ●●●●●●
Novavax's partners have received regulatory approvals for the Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant in the U.S., EU, and Japan. This development allows the company to continue generating royalty revenue from net sales in these key markets.…more
$9.74+0.46%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report